Last reviewed · How we verify

Alzaten — Competitive Intelligence Brief

Alzaten (phentetramine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: phentetramine. Area: Neuroscience.

unknown phentetramine Neuroscience Live · refreshed every 30 min

Target snapshot

Alzaten (phentetramine). Phentetramine is thought to work by activating certain receptors in the brain to increase the release of neurotransmitters.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Alzaten TARGET phentetramine unknown phentetramine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (phentetramine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alzaten — Competitive Intelligence Brief. https://druglandscape.com/ci/phentetramine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing